Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $72.9 million as the latest value for Q4 2022.

  • Quarterly Total Non-Current Liabilities rose 33.72% to $72.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2022, up 33.72% year-over-year, with the annual reading at $72.9 million for FY2022, 33.72% up from the prior year.
  • Total Non-Current Liabilities for Q4 2022 was $72.9 million at Caribou Biosciences, down from $74.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $74.7 million in Q3 2022, with the low at $18.0 million in Q4 2020.
  • Average Total Non-Current Liabilities over 3 years is $60.1 million, with a median of $65.1 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 203.12% in 2021, then soared 30.14% in 2022.
  • Over 3 years, Total Non-Current Liabilities stood at $18.0 million in 2020, then surged by 203.12% to $54.5 million in 2021, then soared by 33.72% to $72.9 million in 2022.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $72.9 million, $74.7 million, and $73.5 million for Q4 2022, Q3 2022, and Q2 2022 respectively.